OSCR

NRF2 Deletion Results in Mobility Impairment in A53TSyn Model of Synucleinopathy.

Overview

Authors: Noah Gladen-Kolarsky1, Lucas Kuhnau1, Wyatt Hack1, Joseph F Quinn1,2, Nora E Gray1
ORCID iDs: Wyatt Hack, Joseph F Quinn
  1. Department of Neurology, Oregon Health & Science University, Portland, OR 97239, USA; (N.G.-K.)
  2. Parkinson’s Disease Research Education and Clinical Care, Center (PADRECC), VA Portland Healthcare System, Portland, OR 97239, USA
Institutions: Oregon Health & Science University (United States); Portland VA Medical Center (United States); VA Portland Health Care System (United States)
Journal: Antioxidants (Basel, Switzerland), volume 15, issue 8, article 926
Dates: received 1 June 2026; accepted 22 July 2026; published online 25 July 2026
Type: Research article · Language: English
License: CC BY
Identifiers: DOI 10.3390/antiox15080926 · PMID 42650189 · PMCID PMC13509511 · OpenAlex W7171393199
Open access: gold, a free copy (OpenAlex)
Status: data only
Categories: behavior only (modality), human (organism), mouse (organism), Parkinson's (population), cellular / molecular (subfield)
Methods: Statistics, fMRI & imaging
Keywords: Parkinson’s, oxidative stress, mobility, NRF2, alpha-synuclein, mice, tyrosine hydroxylase, A53TSyn, gait, open field
Topic: Genomics, phytochemicals, and oxidative stress (Molecular Biology, Biochemistry, Genetics and Molecular Biology), according to OpenAlex
Funding: Ron and Mary Beamer (Philanthropic donation)
Citations: not cited yet (Europe PMC); 42 references in the paper

Abstract

Parkinson’s Disease (PD) is the second most diagnosed neurological disorder globally, affecting millions of people worldwide. Oxidative stress is implicated in the progression of PD, yet its direct effects on motor function, particularly in the context of synucleinopathy, are not fully understood. Here, we investigated the effects of the loss of the antioxidant regulatory transcription factor NRF2 in the A53TSyn mouse model of synucleinopathy. Motor function was evaluated in separate cohorts of A53TSyn mice without NRF2 (A53TSyn/NRF2KO), as well as A53TSyn mice expressing NRF2 (A53TSyn/NRF2+) and healthy wild-type (WT) mice at four, six, and eight months of age. The overall mobility decreased in A53TSyn/NRF2KO mice relative to WT mice at all ages. Significant alterations in gait were also apparent in A53TSyn/NRF2KO mice compared to A53TSyn mice without NRF2 deletion. Expression of tyrosine hydroxylase (TH) was also quantified in the brains of those mice. While there were no differences in cortical pSyn expression between A53TSyn/NRF2+ and A53TSyn/NRF2KO mice, a reduction in TH abundance in the striatum was evident in A53TSyn/NRF2KO mice at all ages. In summary, our data suggest that NRF2 plays a role in maintaining mobility and gait in the context of synucleinopathy and may represent a therapeutic target to mitigate mobility decline in PD-affected individuals.

Reproduced under the paper's license (CC BY), from the paper cited above.

Code

The paper links to its data, not to its authors' code: see the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none, so it has no map.

Data

Datasets cited

Data Availability Statement

The raw data supporting the conclusions of this article will be madeavailable by the authors on request.

Reproduced under the paper's license (CC BY), from the paper cited above.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 1, 27 September 2026: the first record

Recorded: type, language, journal, volume, issue, pages, dates, 5 authors, 10 keywords, 1 funder, 40 references.

Cite

This paper

Gladen-Kolarsky, N., Kuhnau, L., Hack, W., Quinn, J. F., & Gray, N. E. (2026). NRF2 Deletion Results in Mobility Impairment in A53TSyn Model of Synucleinopathy. Antioxidants (Basel, Switzerland), 15(8), 926. https://doi.org/10.3390/antiox15080926

BibTeX

@article{gladenkolarsky2026nrf2,
author = {Gladen-Kolarsky, Noah and Kuhnau, Lucas and Hack, Wyatt and Quinn, Joseph F and Gray, Nora E},
title = {{NRF2 Deletion Results in Mobility Impairment in A53TSyn Model of Synucleinopathy}},
journal = {Antioxidants (Basel, Switzerland)},
year = {2026},
month = jul,
volume = {15},
number = {8},
pages = {926},
publisher = {Multidisciplinary Digital Publishing Institute (MDPI)},
issn = {2076-3921},
doi = {10.3390/antiox15080926},
url = {https://doi.org/10.3390/antiox15080926},
pmid = {42650189},
pmcid = {PMC13509511}
}

RIS

TY - JOUR
AU - Gladen-Kolarsky, Noah
AU - Kuhnau, Lucas
AU - Hack, Wyatt
AU - Quinn, Joseph F
AU - Gray, Nora E
TI - NRF2 Deletion Results in Mobility Impairment in A53TSyn Model of Synucleinopathy
T2 - Antioxidants (Basel, Switzerland)
J2 - Antioxidants (Basel)
PY - 2026
DA - 2026/07/25
VL - 15
IS - 8
SP - 926
SN - 2076-3921
PB - Multidisciplinary Digital Publishing Institute (MDPI)
DO - 10.3390/antiox15080926
UR - https://doi.org/10.3390/antiox15080926
LA - en
ER -

CSL-JSON

{
"id": "10.3390/antiox15080926",
"type": "article-journal",
"title": "NRF2 Deletion Results in Mobility Impairment in A53TSyn Model of Synucleinopathy",
"container-title": "Antioxidants (Basel, Switzerland)",
"author": [
{
"family": "Gladen-Kolarsky",
"given": "Noah"
},
{
"family": "Kuhnau",
"given": "Lucas"
},
{
"family": "Hack",
"given": "Wyatt"
},
{
"family": "Quinn",
"given": "Joseph F"
},
{
"family": "Gray",
"given": "Nora E"
}
],
"container-title-short": "Antioxidants (Basel)",
"volume": "15",
"issue": "8",
"page": "926",
"DOI": "10.3390/antiox15080926",
"PMID": "42650189",
"PMCID": "PMC13509511",
"ISSN": "2076-3921",
"publisher": "Multidisciplinary Digital Publishing Institute (MDPI)",
"URL": "https://doi.org/10.3390/antiox15080926",
"language": "en",
"issued": {
"date-parts": [
[
2026,
7,
25
]
]
}
}

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.1038/s41531-026-01417-5 [code]
Correlation of thalamic functional organization disturbances and genetic architecture in motor subtypes of Parkinson's disease.
Journal: NPJ Parkinson's disease
In common: Parkinson's, 2 references
[2] doi:10.1186/s12929-026-01257-8
Distinct and combined interferon-ɑ/β-receptor-1 loss in neurons and astrocytes disrupt brain energy metabolism and drive Parkinsonian dementia.
Journal: Journal of biomedical science
In common: Parkinson's, mouse, cellular / molecular, 1 reference
[3] doi:10.1111/nan.70097
Transgenic A53T Mice Have Astrocytic α-Synuclein Aggregates in Dopamine and Striatal Regions.
Journal: Neuropathology and applied neurobiology
In common: Parkinson's, mouse, cellular / molecular, 1 reference
[4] doi:10.1186/s12974-026-03910-3
Hereditary spastic paraplegia (HSP) gene 11 (Spg11) attenuates lipid accumulation in myeloid cells and neuroinflammation in the midbrain without affecting α-synuclein pathology.
Journal: Journal of neuroinflammation
In common: Parkinson's, mouse, cellular / molecular, 1 reference
[5] doi:10.1016/j.nbd.2026.107379 [code]
DYRK1A and Parkinson's disease, facts and hypotheses.
Journal: Neurobiology of disease
In common: Parkinson's, cellular / molecular, 1 reference
[6] doi:10.1007/s12031-026-02506-z
Striatal Dysregulation of Angpt2 and Circadian Gene Expression in a Rotenone Rat Model of Parkinson's Disease.
Journal: Journal of molecular neuroscience : MN
In common: Parkinson's, cellular / molecular, 1 reference
[7] doi:10.3390/metabo16080541
Spatial Metabolomics and Single-Cell Virtual Knockout Screening Reveal Solanesol Improves Parkinson's Disease-like Pathology Based on Lipid Inflammation Mechanism.
Journal: Metabolites
In common: Parkinson's, cellular / molecular, 1 reference
[8] doi:10.7717/peerj-cs.3860
Systematic review of unveiling the potential of AI using machine learning and deep learning methods in neurodegenerative diseases.
Journal: PeerJ. Computer science
In common: Parkinson's, 1 reference
[9] doi:10.1002/advs.76989
Targeting Hippocampal PTEN Suppresses Ferroptosis and Rescues Cognitive Decline in Alzheimer's Disease via Dual AKT/GSK3β/Nrf2 and AKT/STAT3 Axes.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
In common: mouse, cellular / molecular, 1 reference
[10] doi:10.3389/fvets.2026.1770540
<i>γ</i>-Aminobutyric acid enhances myogenesis and heat/cold stress resistance in bovine muscle satellite cells.
Journal: Frontiers in veterinary science
In common: cellular / molecular, 1 reference

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion, reproductions, activity

Discussion: questions and error reports about this paper and its code, from signed-in readers and its authors. It opens with sign-in.

Reproductions: reports from readers who ran the authors' code: what they reproduced, with which environment, commit and data. It opens with sign-in.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.